I finally got my wife's insurer (Regence Blue Cross of Oregon) to pay for her Oncotype test, but only after going through three appeals (the last to an Independent Review Organization). Regence said it was excluded as experimental or investigational. The IRO reversed the insurer, relying heavily upon the fact that the TailorX study essentially takes as a given the fact that Oncotype has been shown to predict the lack of benefit of chemo for those with RS less than 11. The link to a NIH document discussing TailorX and the validity of the Oncotype test is here:
http://www.nih.gov/news/pr/may2006/nci-23.htm.
The brief I submitted in my appeal to the insurer didn't mention TailorX, but bolstered the findings of the IRO. My brief is too long to post, but if you want a copy email me at [email protected] and I will send it to you.
Good luck, and don't them run you over!